From the Research
I strongly advise against taking Skyrizi (risankizumab) together with Venclexta (venetoclax, which I assume is what you meant by "vengesi") without explicit approval from your healthcare provider. These medications are used for completely different conditions - Skyrizi is an immunosuppressant used for psoriasis and psoriatic arthritis, while Venclexta is an anti-cancer medication used primarily for certain blood cancers like chronic lymphocytic leukemia. Taking these medications together could potentially cause harmful drug interactions or compound side effects, particularly related to immune system function. Both medications can affect your body's ability to fight infections, though through different mechanisms. Additionally, each medication has its own monitoring requirements and potential side effects that need careful management. If you're currently prescribed one of these medications and considering the other, it's essential to have a thorough discussion with your doctor about your complete medical history, current conditions, and all medications you're taking to ensure safe and effective treatment.
The provided evidence does not directly address the interaction between Skyrizi and Venclexta, but it highlights the efficacy and safety of Skyrizi in treating moderate to severe plaque psoriasis, as seen in studies such as 1 and 2. However, the primary concern here is the potential for adverse interactions and the importance of careful management when considering the use of multiple medications with different mechanisms of action, as noted in general medical practice.
Some key points to consider when evaluating the use of Skyrizi include:
- Its efficacy in achieving significant improvements in Psoriasis Area and Severity Index (PASI) scores, as demonstrated in studies like 1 and 3.
- The safety profile of Skyrizi, which has been shown to be generally well-tolerated in long-term use, as reported in 2.
- The importance of monitoring and managing potential side effects, as with any immunosuppressive therapy.
Given the lack of direct evidence regarding the combination of Skyrizi and Venclexta, the most prudent approach is to consult with a healthcare provider to discuss the potential risks and benefits and to determine the best course of treatment based on individual patient needs and medical history.